Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope. The initiative is promoting lung cancer screening and efforts to fund research, as well as releasing an upcoming report. Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more. Lung Cancer Awareness Month is observed every November and represents a key time to take action and raise awareness. The campaign, titled "Anyone with Lungs Can Get Lung Cancer," includes multiple virtual and in-person components. Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation. Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level. The meeting will be held September 12-15, 2026, in Seoul, South Korea. The registry, launched by the Florez Lab in 2023, is collecting data from around the world. Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer. Officials plan to submit a supplemental New Drug Application for the use of the combination therapy in this setting. Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing. Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician. Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting. Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement. Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study. Jill Feldman, a patient advocate, discusses how the lexicon can improve communication and empower patients. The results of the phase 3 NRG Oncology/Alliance LU005 trial were presented during the 2024 ASTRO Annual Meeting. Dr. Li discusses important thoracic oncology data presented at the ESMO 2024 Congress, which was held in Barcelona, Spain Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.